SCYNEXIS INC - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by SCYNEXIS, Inc. on February 11, 2015, reporting events that occurred on February 5, 2015. The filing addresses significant changes in executive leadership effective April 1, 2015.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
- Resignation of CEO: Yves J. Ribeill, Ph.D., will resign as Chief Executive Officer effective April 1, 2015. He will remain as President and a member of the Board of Directors with no changes to his existing compensation.
- Appointment of CEO: Dr. Marco Taglietti was appointed as the new Chief Executive Officer, effective April 1, 2015. Dr. Taglietti has served on the Board since November 2014 and brings nearly 30 years of industry experience, including leadership roles at Forest Laboratories, Stiefel Laboratories, and Schering-Plough.
Compensation and Employment Terms
Dr. Taglietti's new employment agreement includes the following terms:
- Base Salary: $480,000 annually.
- Discretionary Bonus: Eligible for up to 50% of annual base salary.
- Initial Stock Option: Option to purchase 330,000 shares of common stock. Vesting schedule: 25% on the one-year anniversary, with the remainder vesting in equal monthly installments over 36 months.
- Additional Stock Option: Subject to Board approval, an additional option for 80,000 shares will be granted on the first anniversary of employment, vesting monthly over 48 months.
- Severance (Termination without Cause/Good Reason): 12 months of base salary and acceleration of unvested equity as if 12 additional months of service were completed.
- Change of Control Severance: If terminated within 12 months of a change of control, Dr. Taglietti is entitled to 24 months of base salary and 100% acceleration of unvested equity.
Investor Verification Checklist
- Confirm the effective date of the leadership transition (April 1, 2015).
- Verify the total potential equity grant (330,000 initial shares + 80,000 potential additional shares).
- Review the specific definitions of "just cause" and "good reason" in the employment agreement to understand severance triggers.
- Monitor future filings for the Board's approval of the additional 80,000 share option grant.